New Hope for Patients with Pancreatic Cancer
In this episode of Science Snapshot, learn how a new once-daily pill called daraxonrasib is nearly doubling median survival for previously treated metastatic pancreatic cancer patients.
Mutations in the KRAS gene are some of the most common drivers of all types of cancers—especially pancreatic cancer. For a long time, KRAS mutations have been considered “undruggable," but new trial results suggest that a once-daily pill, daraxonrasib, can nearly double median survival in previously treated metastatic pancreatic cancer.
How does it work? Watch the full video for the science behind the breakthrough.
Explore a Related Course
Cancer Genomics and Precision Oncology: The Genetic Basis of Cancer and Its Treatment
Understand the links between genetics and cancer, and how genomics knowledge is advancing precision cancer treatments.
- HMX Online Learning
- Online; Instructor-Paced
Dates: -
For: Clinicians; biomedical researchers; health care professionals whose work intersects with cancer research and treatment – including those working in R&D, product management and strategy, sales, and marketing